Paramount Biosciences is a prolific founder of development biotech and life sciences companies
Paramount BioSciences is a global pharmaceutical development and healthcare investment firm that conceives, nurtures, and supports new biotechnology and life sciences companies. The Paramount BioSciences team – comprising a broad spectrum of drug developers, MDs, PhDs, finance professionals, attorneys, accountants, and analysts – provides its portfolio companies with a wide-range of professional and support services.

For nearly 20 years since its founding, Paramount BioSciences has created and/or substantially financed over 40 companies, including about two dozen in the past three years alone. Paramount BioSciences’ current portfolio companies have scores of product candidates in clinical trials at this time and many more in pre-clinical development.

In-licensed compounds progess efficiently through the clinic
Paramount’s startup companies are predicated on the continued clinical development of in-licensed compounds. For that reason, each product is developed with maximum attention and efficiency; no drug candidate is “shelved.” Arsenic Trioxide, a cancer drug in-licensed by one of Paramount’s portfolio companies received final marketing approval within 32 months after the first patient was dosed in a company-sponsored clinical trial, a record in the industry at the time.

Companies are supported by superior personnel and infrastructure
Once drug candidates are in-licensed, Paramount’s proven track record allows it to attract and recruit premium management personnel. Recent Paramount CEO hires include former senior executives of Johnson & Johnson, Biogen Idec, Amgen and Roche. Paramount seeks to provide its portfolio companies the highest level of support in all aspects of management and corporate development, including clinical development, regulatory, legal and financial matters.

Companies are well-financed and focused on clinical achievements
Paramount BioSciences dedicates its own capital to seed companies through formation, the in-licensing of drug candidates and the initial stages of product development. Through its FINRA-registered broker-dealer affiliate, Paramount raises additional funds from investors, typically taking its affiliated companies public and gaining them exposure to the investment community. Paramount’s experience in developing life sciences companies allows management to remain focused on the development of drug candidates rather than building infrastructure. Paramount believes that its model helps limit developmental delays occasioned by management distraction and facilitates management effectiveness.

Premium placed on clinical stage compounds
Paramount BioSciences seeks compounds that have demonstrated proof of concept in early stages of clinical development. Paramount also assesses various types of intellectual property, use patents, new indications and formulations for existing compounds.

Contact Information
Headquarters: